Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab

BNB PLUS CORP.

Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.
One-time charges of ~$300k; majority of costs expected by Sept 30, 2025.
CEO Judy Murrah takes 15% salary reduction to $340k/year.
Company ends May 2025 with ~$4.8M cash; cumulative headcount reduction of 39% since Dec 2024.
Restructuring positions LineaRx synthetic DNA manufacturing as sole focus.

item 2.05item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.